<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0003613'>Antiphospholipid antibody</z:hpo> syndrome (APLAS) characterises a clinical condition of arterial and <z:hpo ids='HP_0004936'>venous thrombosis</z:hpo> associated with <z:chebi fb="1" ids="16247">phospholipids</z:chebi> directed antibodies </plain></SENT>
<SENT sid="1" pm="."><plain>APLAS occurs in 2% of the general population </plain></SENT>
<SENT sid="2" pm="."><plain>However, one study demonstrated that 7.1% of hospitalised patients were tested positive for at least one of the three anticardiolipin antibody idiotype </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0003613'>Antiphospholipid antibodies</z:hpo> often inhibit <z:chebi fb="1" ids="16247">phospholipids</z:chebi> dependent coagulation in vitro and interfere with laboratory testing of hemostasis </plain></SENT>
<SENT sid="4" pm="."><plain>Therefore, the management of anticoagulation during cardiopulmonary bypass can be quite challenging in these patients </plain></SENT>
<SENT sid="5" pm="."><plain>Here, we present a case of right atrial mass removal and pulmonary thrombectomy in a patient of APLAS </plain></SENT>
</text></document>